Kitze, Bernd

[["dc.bibliographiccitation.firstpage","822"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","European Journal of Neurology"],["dc.bibliographiccitation.lastpage","826"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Millonig, A."],["dc.contributor.author","Dressel, Alexander"],["dc.contributor.author","Bahner, D."],["dc.contributor.author","Bitsch, Annette"],["dc.contributor.author","Bogumil, T."],["dc.contributor.author","Elitok, E."],["dc.contributor.author","Kitze, Bernd"],["dc.contributor.author","Tumani, Hayrettin"],["dc.contributor.author","Weber, F."],["dc.contributor.author","Gneiss, C."],["dc.contributor.author","Deisenhammer, Florian"],["dc.date.accessioned","2018-11-07T11:12:24Z"],["dc.date.available","2018-11-07T11:12:24Z"],["dc.date.issued","2008"],["dc.description.abstract","Background and purpose: Interferon beta (IFN beta) preparations have some effect on the progressive phase of multiple sclerosis ( MS). This limited effect might be partially because of a certain number of IFN beta non-responders. Myxovirus resistance protein A (MxA)-a marker of IFN beta bioactivity - was correlated with the clinical response during an uncontrolled trial, investigating the safety of IFN beta-1 beta in primary progressive (PPMS) patients. Methods: Twenty PPMS were treated with IFN beta-1 beta (s.c.) for 1 year. Blood samples were taken before and 1, 2, 3, 6, 9, 12, and 15 months after treatment initiation and MxA protein levels were measured. Patients were clinically evaluated by EDSS and the more sensitive Incapacity Status Scale (ISS) and stratified in a stable and a progressing group. Results: Using ISS criteria, 11 patients remained stable and nine patients progressed during treatment. The mean area under the curve of log MxA levels during treatment were significantly higher in stable than in progressing patients (10.87 vs. 5.99; P = 0.002). Conclusion: A good biological response to IFNb might be associated with a better clinical effect of this drug and could be helpful in future clinical studies for early identification of treatment responders."],["dc.identifier.doi","10.1111/j.1468-1331.2008.02190.x"],["dc.identifier.isi","000257715400022"],["dc.identifier.pmid","18549400"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53656"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1351-5101"],["dc.title","MxA protein - an interferon beta biomarker in primary progressive multiple sclerosis patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1498"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Journal of Neurology"],["dc.bibliographiccitation.lastpage","1501"],["dc.bibliographiccitation.volume","251"],["dc.contributor.author","Bitsch, Annette"],["dc.contributor.author","Dressel, Alexander"],["dc.contributor.author","Meier, K."],["dc.contributor.author","Bogumil, T."],["dc.contributor.author","Deisenhammer, Florian"],["dc.contributor.author","Tumani, Hayrettin"],["dc.contributor.author","Kitze, Bernd"],["dc.contributor.author","Poser, Sigrid"],["dc.contributor.author","Weber, F."],["dc.date.accessioned","2018-11-07T10:43:31Z"],["dc.date.available","2018-11-07T10:43:31Z"],["dc.date.issued","2004"],["dc.description.abstract","We conducted an open-labeled clinical trial of interferon beta-1b (IFNB) treatment in 20 patients with primary progressive multiple sclerosis (PPMS) and longitudinally monitored autoantibodies against double-stranded DNA (dsDNA), thyroid peroxidase (TPO),myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), synapsin and S-100B. Before treatment, one patient had elevated TPO antibodies, four patients had elevated antibodies against S-100B, two patients against MOG or synapsin and one patient against MBP. In two patients we observed a continuous increase of dsDNA or TPO antibodies above the normal range. This rise paralleled IFNB treatment. In addition, 11 of 20 patients developed neutralizing antibodies against IFNB. There was no increase of autoantibodies directed against central nervous system antigens. Like patients with relapsing remitting or secondary progressive multiple sclerosis, PPMS patients may be at risk of an autoimmune response during IFNB treatment."],["dc.identifier.doi","10.1007/s00415-004-0580-3"],["dc.identifier.isi","000226302000010"],["dc.identifier.pmid","15645350"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47070"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","0340-5354"],["dc.title","Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1224"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Journal of Neurology"],["dc.bibliographiccitation.lastpage","1228"],["dc.bibliographiccitation.volume","250"],["dc.contributor.author","Yushchenko, M."],["dc.contributor.author","Mader, M."],["dc.contributor.author","Elitok, E."],["dc.contributor.author","Bitsch, Annette"],["dc.contributor.author","Dressel, Alexander"],["dc.contributor.author","Tumani, Hayrettin"],["dc.contributor.author","Bogumil, T."],["dc.contributor.author","Kitze, Bernd"],["dc.contributor.author","Poser, Sigrid"],["dc.contributor.author","Weber, F."],["dc.date.accessioned","2018-11-07T10:35:52Z"],["dc.date.available","2018-11-07T10:35:52Z"],["dc.date.issued","2003"],["dc.description.abstract","Recent reports have shown that matrix-metalloproteinases (MMPs) facilitate T-cell migration into the CNS and play a role in disruption of the blood-brain-barrier and myelin breakdown. An increase of MMP-9 serum levels predicts disease activity in relapsing remitting multiple sclerosis (RRMS). Interferon-beta (IFN-beta), which is an established treatment for RRMS, inhibits T-cell migration in vitro in parallel with the downregulation of MMP expression. Only limited data are available for primary progressive multiple sclerosis (PPMS) which differs in demographic and immunological aspects as well as in MRI criteria from RRMS. In this study, 19 patients with laboratory-supported definite PPMS were treated with 8 x 10(6) IU IFN-beta1b (Betaferon(R)) subcutaneously every other day. Serum was collected before treatment and on months 1, 2, 3,6 and 9 during treatment. Levels of MMP-9 and of its natural inhibitor known as tissue-inhibitor of matrix-metalloproteinase-1 (TIMP-1) were quantified by ELISA. In addition MMP-2 serum levels were determined by zymography. 19 healthy volunteers served as controls. Before treatment serum levels of MMP-9 were elevated in patients with PPMS compared with controls, whereas there was no difference in TIMP-1 serum levels. During treatment with IFN-beta1b the concentration of MMP-9 in the serum of 18 out of 19 PPMS patients decreased, whereas serum levels of MMP-2 and TIMP-1 remained nearly unaffected. Our results demonstrate that the MMP-9 to TIMP-1 ratio in patients with PPMS is elevated in comparison with healthy controls. The suppression of MMP-9 by IFN-beta1b indicates that this drug is immunomodulatory active in PPMS patients. Further studies are necessary to test if IFN-beta exerts a beneficial effect in PPMS."],["dc.identifier.doi","10.1007/s00415-003-0191-4"],["dc.identifier.isi","000186231900015"],["dc.identifier.pmid","14586607"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45190"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Dr Dietrich Steinkopff Verlag"],["dc.relation.issn","0340-5354"],["dc.title","Interferon-beta-1b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","211"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","EUROPEAN JOURNAL OF DERMATOLOGY"],["dc.bibliographiccitation.lastpage","212"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Amschler, Katharina"],["dc.contributor.author","Meyersburg, Damian"],["dc.contributor.author","Kitze, Bernd"],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Moessner, Rotraut"],["dc.date.accessioned","2018-11-07T10:17:02Z"],["dc.date.available","2018-11-07T10:17:02Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1684/ejd.2015.2602"],["dc.identifier.isi","000377180000029"],["dc.identifier.pmid","27125193"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41152"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","John Libbey Eurotext Ltd"],["dc.relation.issn","1952-4013"],["dc.relation.issn","1167-1122"],["dc.title","Onset of psoriasis upon interferon beta treatment in a multiple sclerosis patient"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","PII S0304-3940(02)00311-7"],["dc.bibliographiccitation.firstpage","125"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Neuroscience Letters"],["dc.bibliographiccitation.lastpage","128"],["dc.bibliographiccitation.volume","326"],["dc.contributor.author","Bahner, D."],["dc.contributor.author","Klucke, C."],["dc.contributor.author","Kitze, Bernd"],["dc.contributor.author","Elitok, E."],["dc.contributor.author","Bogumil, T."],["dc.contributor.author","Dressel, Alexander"],["dc.contributor.author","Tumani, Hayrettin"],["dc.contributor.author","Weber, F."],["dc.contributor.author","Poser, Sigrid"],["dc.contributor.author","Bitsch, Annette"],["dc.date.accessioned","2018-11-07T10:24:34Z"],["dc.date.available","2018-11-07T10:24:34Z"],["dc.date.issued","2002"],["dc.description.abstract","Serum levels of interleukin-12 heterodimer (IL-12p70) and its homodimeric subunit (IL-12p40) were analyzed by enzyme-linked immunosorbent assay in 18 patients with primary progressive multiple sclerosis (MS) during 3 months before and 3 months under treatment with interferon-beta-1b (IFNbeta-1b, Betaferon(TM), eight million units (MIU) every other day subcutaneously). Median IL-12p40 levels in MS patients before treatment (66.5 and 63.9 pg/ml) were not elevated compared to 18 healthy controls. IL-12p40 significantly increased during treatment (P < 0.0001, median 105.3 pg/ml after 1 month and 95.3 pg/ml after 3 months). Detectable serum levels of IL-12p70 before therapy were only found in one patient. IL-12p70 did not increase during treatment. These data show that immunological processes may also play a role in primary progressive MS and that IFNbeta-1b has an immunomodulating effect in this particular MS subtype. (C) 2002 Published by Elsevier Science Ireland Ltd."],["dc.identifier.doi","10.1016/S0304-3940(02)00311-7"],["dc.identifier.isi","000176623000014"],["dc.identifier.pmid","12057844"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42687"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","0304-3940"],["dc.title","Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","AIDS Research and Human Retroviruses"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Kitze, Bernd"],["dc.contributor.author","Nacimiento, W."],["dc.contributor.author","Uhlenhaut, C."],["dc.contributor.author","Pauli, G."],["dc.date.accessioned","2018-11-07T11:01:22Z"],["dc.date.available","2018-11-07T11:01:22Z"],["dc.date.issued","2005"],["dc.format.extent","464"],["dc.identifier.isi","000229825700087"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51137"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Mary Ann Liebert Inc"],["dc.publisher.place","New rochelle"],["dc.relation.conference","12th International Conference on Human Retrovirology - HTLV and Related Viruses"],["dc.relation.eventlocation","Montego Bay, JAMAICA"],["dc.relation.issn","0889-2229"],["dc.title","Brachial plexopathy as an early manifestation of Ham/Tsp and successful treatment with Ifn-alpha"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","197"],["dc.bibliographiccitation.lastpage","211"],["dc.bibliographiccitation.seriesnr","265"],["dc.contributor.author","Kitze, Bernd"],["dc.contributor.author","Usuku, K."],["dc.date.accessioned","2018-11-07T10:33:43Z"],["dc.date.available","2018-11-07T10:33:43Z"],["dc.date.issued","2002"],["dc.identifier.isi","000176281200010"],["dc.identifier.pmid","12014190"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44681"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Berlin"],["dc.relation.crisseries","Current Topics in Microbiology and Immunology"],["dc.relation.isbn","3-540-42668-X"],["dc.relation.ispartof","Protective and pathological immune responses in the CNS"],["dc.relation.ispartofseries","Current topics in microbiology and immunology; 265"],["dc.title","HTLV-1-mediated immunopathological CNS disease"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","AIDS Research and Human Retroviruses"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Kitze, Bernd"],["dc.contributor.author","Usuku, K."],["dc.date.accessioned","2018-11-07T10:41:49Z"],["dc.date.available","2018-11-07T10:41:49Z"],["dc.date.issued","2003"],["dc.format.extent","S46"],["dc.identifier.isi","000183280000134"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/46626"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Mary Ann Liebert Inc Publ"],["dc.publisher.place","Larchmont"],["dc.relation.conference","11th International Conference on Human Retrovirology: HTLV and Related Viruses"],["dc.relation.eventlocation","SAN FRANCISCO, CALIFORNIA"],["dc.relation.issn","0889-2229"],["dc.title","B-cell immune response in HAM/TSP."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","132"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","AKTUELLE NEUROLOGIE"],["dc.bibliographiccitation.lastpage","134"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Weber, F."],["dc.contributor.author","Neurath, H."],["dc.contributor.author","Desel, Herbert"],["dc.contributor.author","Kitze, Bernd"],["dc.contributor.author","Prange, Hilmar"],["dc.date.accessioned","2018-11-07T09:10:47Z"],["dc.date.available","2018-11-07T09:10:47Z"],["dc.date.issued","2001"],["dc.description.abstract","Venlafaxin is a serotonine-noradrenaline reuptake inhibitor that is used for treatment of depression and concomitant anxiety disorders. We report on a 38 years old woman, who developed a generalised seizure, agitation and somnolence, fever, hyponatriemia, rhabdomyolysis and a tachyarrhytmia absoluta. In a blood sample, which was collected about one day after the ingestion of venlafaxin, we detected 12 ng/ml venlafaxin and 105 ng/ml of its active metabolite O-desmethyl-venlafaxin. Considering the pharmacokinetic of venlafaxin and O-desmethyl-venlafaxin toxic plasma levels of both substances can be calculated for the time when symptoms had occurred. Under treatment with volume, diuretics and substitution of electrolytes the patient recovered consciousness very quickly. However, serum levels of creatine-kinase increased steadily to a maximum of 14 926 U/I on day 3 and declined slowly thereafter. In addition, a tachyarrhytmia absoluta developed suddenly on day 4 and reversed spontaneously one day later. While seizures, fever, hyponatriemia and loss of consciousness are typical symptoms of intoxication with venlafaxin, rhabdomyolysis and the late occurrence of tachyarrhytmia absoluta are uncommon."],["dc.identifier.doi","10.1055/s-2001-12522"],["dc.identifier.isi","000168288700008"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26573"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0302-4350"],["dc.title","Rhabdomyolysis after intake of Venlafaxin"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","4121"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Anticancer Research"],["dc.bibliographiccitation.lastpage","4125"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Strik, Herwig M."],["dc.contributor.author","Spreer, Annette"],["dc.contributor.author","Nagel, Holger"],["dc.contributor.author","Jacob, Sonja"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Kitze, Bernd"],["dc.contributor.author","Bähr, Mathias"],["dc.date.accessioned","2017-09-07T11:43:10Z"],["dc.date.available","2017-09-07T11:43:10Z"],["dc.date.issued","2004"],["dc.description.abstract","A 69-year-old female patient was treated for primary CNS-lymphoma (PCNSL) starting from August 2002. As her general condition allowed no high-dose methotrexate (MTX) therapy, radiotherapy was administered as a first-line treatment. CSF involvement could be managed by intrathecal Ara-C. Her general condition and cognitive status stabilized., but did not improve for 3 months. Therefore, oral chemotherapy with Temozolomide 200mg/m(2) was initiated. After two courses, which were tolerated without any problems, the patient's Karnofsky performance index had improved from 40% to 50%, the Mini-Mental Status rose from 16 to 27130. The CSF-cell count was elevated again to 23 cells/mul without signs of meningeal relapse. Unfortunately, the patient died unexpectedly front suspected pulmonary embolism. We conclude that adjuvant Temozolomide chemotherapy can improve the general condition and cognition in patients with PCNSL even when the general condition is poor. Long-term effects and neurotoxicity remain to be analysed in prospective trials, as well as the efficacy in leptomeningeal disease."],["dc.identifier.gro","3143931"],["dc.identifier.isi","000227014500066"],["dc.identifier.pmid","15736462"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/1499"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","0250-7005"],["dc.title","Clinical Response Following Adjuvant Temozolomide in a Patient with Primary Cerebral Lymphoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]